[go: up one dir, main page]

WO2009004339A3 - Modulation of reactive oxygen species in the treatment of respiratory infection - Google Patents

Modulation of reactive oxygen species in the treatment of respiratory infection Download PDF

Info

Publication number
WO2009004339A3
WO2009004339A3 PCT/GB2008/002280 GB2008002280W WO2009004339A3 WO 2009004339 A3 WO2009004339 A3 WO 2009004339A3 GB 2008002280 W GB2008002280 W GB 2008002280W WO 2009004339 A3 WO2009004339 A3 WO 2009004339A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
relates
oxygen species
reactive oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/002280
Other languages
French (fr)
Other versions
WO2009004339A2 (en
Inventor
Tracy Hussell
Robert Snellgrove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Publication of WO2009004339A2 publication Critical patent/WO2009004339A2/en
Publication of WO2009004339A3 publication Critical patent/WO2009004339A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to therapeutic compositions for use in treating, ameliorating or preventing an infection such as a microbial infection in a subject, comprising a compound modulative of reactive oxygen species level, or CD200 level, or CD200R level, or a combination of two or more of said levels in said subject. The invention also relates to methods of treatment using such compositions. In addition, the invention relates to therapeutic compositions for use in treating, ameliorating or preventing an inflammatory pulmonary infection in a mammalian host having a CD200-CD200R axis comprising a compound modulative of said axis, and to methods of treatment using such compositions. Furthermore, the invention relates to therapeutic compositions for use in treating, ameliorating or preventing a microbial infection and/or pulmonary inflammation in a subject comprising a compound mimetic of superoxide dismutase, and to methods of treatment using such compositions.
PCT/GB2008/002280 2007-07-03 2008-07-03 Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection Ceased WO2009004339A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95832907P 2007-07-03 2007-07-03
US60/958,329 2007-07-03

Publications (2)

Publication Number Publication Date
WO2009004339A2 WO2009004339A2 (en) 2009-01-08
WO2009004339A3 true WO2009004339A3 (en) 2009-10-22

Family

ID=39720324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002280 Ceased WO2009004339A2 (en) 2007-07-03 2008-07-03 Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection

Country Status (1)

Country Link
WO (1) WO2009004339A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) * 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030223991A1 (en) * 2002-03-15 2003-12-04 Cherwinski Holly M. Methods of modulating CD200 receptors
WO2004060295A2 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
EP1616869A1 (en) * 1999-01-25 2006-01-18 National Jewish Medical and Research Center Substituted porphyrins and their therapeutic use
WO2007084321A2 (en) * 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616869A1 (en) * 1999-01-25 2006-01-18 National Jewish Medical and Research Center Substituted porphyrins and their therapeutic use
US20030223991A1 (en) * 2002-03-15 2003-12-04 Cherwinski Holly M. Methods of modulating CD200 receptors
WO2004060295A2 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
WO2007084321A2 (en) * 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
R. SNELGROVE, E. GWYER, T. HUSSELL: "Modulation of immunity to respiratory viral infection", FUTURE VIROLOGY, vol. 1, no. 4, July 2006 (2006-07-01), pages 471 - 481, XP001538706 *
SNELGROVE ET AL.: "Manipulation of CD200 signalling offers therapeutic potential against respiratory infectious disease", IMMUNOLOGY, vol. 113, 2004, pages 5 - 7, XP002538514 *
SNELGROVE R J ET AL: "In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection", JOURNAL OF IMMUNOLOGY 20061015 US, vol. 177, no. 8, 15 October 2006 (2006-10-15), pages 5509 - 5516, XP009105538, ISSN: 0022-1767 *
SNELGROVE ROBERT J ET AL: "A critical function for CD200 in lung immune homeostasis and the severity of influenza infection", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 9, no. 9, 27 July 2008 (2008-07-27), pages 1074 - 1083, XP009105540, ISSN: 1529-2908, [retrieved on 20080727] *
SNELGROVE ROBERT J ET AL: "An absence of reactive oxygen species improves the resolution of lung influenza infection.", EUROPEAN JOURNAL OF IMMUNOLOGY JUN 2006, vol. 36, no. 6, June 2006 (2006-06-01), pages 1364 - 1373, XP002495187, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
WO2009004339A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
MX2011011768A (en) Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both.
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
ATE539079T1 (en) IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS
IN2012DN00624A (en)
MX337933B (en) Novel compositions for preventing and/or treating lysosomal storage disorders.
WO2014027965A8 (en) Wound dressing nanomesh impregnated with human umbilical cord wharton's jelly stem cells
SE0501556L (en) Increased absorption
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2011133890A8 (en) Cns targeting aav vectors and methods of use thereof
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007090068A3 (en) Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
WO2009060292A3 (en) Smac mimetic compounds as apoptosis inducers
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2011159840A3 (en) Phenylthioacetate compounds, compositions and methods of use
WO2014086764A3 (en) Composition comprising a biological control agent and a fungicide
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2008027547A3 (en) Antioxidant therapies
AU2007211617A8 (en) Hydrogel
WO2008132021A3 (en) Fungicide mixtures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775830

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08775830

Country of ref document: EP

Kind code of ref document: A2